US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
USOTC
L A M Y (PK) (LMMY) 銘柄情報

L A M Y (PK) (LMMY)

0.36

0.00

(0.00%)

終了 6月14日 5:00AM

L A M Y (PK) (LMMY) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.36

( - )

買値

0.18

売値

0.47

出来高

-

0.00 日の範囲 0.00

0.06 52 週間の範囲 0.94

時価総額

前日終値

0.36

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 1,586

発行済株式数

73,500,000

配当利回り

PER

-46.77

1 株当たり利益 (EPS)

-0.01

歳入

-

純利益

-80.16k

LAMY designs, develops, and operates an eLearning and gaming marketplace platform. It offers TwoPlus1, an educational video game that provides financial knowledge and resource management to children. The company was incorporated in 2022 and is based in New York, New York. LAMY designs, develops, and operates an eLearning and gaming marketplace platform. It offers TwoPlus1, an educational video game that provides financial knowledge and resource management to children. The company was incorporated in 2022 and is based in New York, New York.

セクター

-

業界

-

本社

New York, United States

設立

2026

L A M Y (PK) is listed in the sector of the その他OTC with ticker LMMY. The last closing price for L A M Y (PK) was US$0.36. Over the last year, L A M Y (PK) shares have traded in a share price range of US$ 0.06 to US$ 0.94.

L A M Y (PK) currently has 73,500,000 shares in issue. The market capitalisation of L A M Y (PK) is US$26.46 million. L A M Y (PK) has a price to earnings ratio (PE ratio) of -46.77.

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Renowned Immunologist and Urological Surgeon Dr. Marvin Hausman Featured in New Exousia Bio, Inc. Interview

Drawing on over 50 years of drug development experience, Dr. Hausman strengthens the Company’s mission to...

LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.

EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- LAMY...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0.36	0.36	0.36	2500	0.36	CS
4	-0.11	-23.4042553191	0.47	0.47	0.36	1198	0.37143294	CS
12	-0.022	-5.75916230366	0.382	0.5	0.315	1340	0.40684495	CS
26	0	0	0.36	0.5	0.26	1951	0.38405343	CS
52	0.2	125	0.16	0.94	0.06	5305	0.29630275	CS
156	0.16	80	0.2	16	0.06	10046	3.89349142	CS
260	0.16	80	0.2	16	0.06	10046	3.89349142	CS

LMMY - Frequently Asked Questions (FAQ)

What is the current L A M Y (PK) share price?

The current share price of L A M Y (PK) is US$ 0.36

How many L A M Y (PK) shares are in issue?

L A M Y (PK) has 73,500,000 shares in issue

What is the market cap of L A M Y (PK)?

The market capitalisation of L A M Y (PK) is USD 26.46M

What is the 1 year trading range for L A M Y (PK) share price?

L A M Y (PK) has traded in the range of US$ 0.06 to US$ 0.94 during the past year

What is the PE ratio of L A M Y (PK)?

The price to earnings ratio of L A M Y (PK) is -46.77

What is the registered address of L A M Y (PK)?

The registered address for L A M Y (PK) is 201 Allen Street, New York, New York, 10002

bjl

$LMMY – Exousia Bio is seeking ways to expand upon its Orphan Drug Designation for Malignant glioma. Our science and medical team are researching rare diseases with unmet medical needs. We plan to file for multiple Orphan Drug Designations under our existing approved Orphan Drug Designation, for these rare diseases, further enhancing the value of our technology.
https://t.co/byeneKUzOn— @ExousiaBio (@ExousiaBio) December 10, 2025

EpicSage

EpicSage 6月前

$LMMY MASSIVE News! LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc. AND Exousia AI Secures High-Value Orphan Drug Designation

AND Company has secured two exclusive worldwide licenses for Exosome technology!

Read the PR: https://globenewswire.com/news-release/2025/12/02/3198199/0/en/LAMY-Completes-Strategic-Acquisition-of-Cancer-Therapy-Innovator-Exousia-AI-Inc.html

DeafTrader2

DeafTrader2 7月前

RM done last Nov. 17 that no one noticed . mak in easy money caught this like a skillful fisher .

DeafTrader2

DeafTrader2 7月前

LMMY is a monster stock ticker that everyone is still overlook this. mak in ez money has the most prized . Congratulations .

makinezmoney

makinezmoney 7月前

$LMMY: Yes....... there are..........

But you have to VENMO me $8,493 as a christmas gift ......... then I will give them to you.

Have a GREAT DAYYYYyyyyyyyyyyyyyyyyyyyyyyyyy

GO $LMMY !!!!!

DeafTrader2

DeafTrader2 7月前

( I cannot DM you ) . Do you have any other tickers that I should buy and hold ?

DeafTrader2

DeafTrader2 7月前

makinezmoney

makinezmoney 7月前

$LMMY: Added 10k here at $0.36 today

Got my interest now.

LFG !!!!!!!!

GO $LMMY

DeafTrader2

DeafTrader2 7月前

LMMY is awakening now .

American Express

Bmo Aggregate Bond Etf F...

Granite 3s Gfam

Exchange Traded Commodit...

Eqty Lkd Nts 28/05/26

Texas Roadhouse

Miguet Et Associes

Ci High Yield Bond Corpo...

TG Therapeutics

Acorn Capital Investment

Departement Bouches du R...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。